Table 1.
Baseline characteristics in different subgroups patients.
| Study population N = 1428 | No-event N = 1387 | Ischaemic stroke N = 32 | Intracranial haemorrhage N = 9 | P value (no-event vs IS) | P value (no-event vs ICH) | P value (IS vs ICH) | |
| Epidemiology data | |||||||
| Age, yrs | 63.07 ± 11.44 | 62.86 ± 11.37 | 69.44 ± 10.99 | 73.22 ± 14.11 | .001 | .007 | .398 |
| Male, n (%) | 1207 (84.52%) | 1172 (84.50%) | 27 (84.38%) | 8 (88.89%) | .985 | .717 | .735 |
| BMI, kg/m2 | 26.53 ± 3.82 | 26.55 ± 3.83 | 26.2 ± 3.58 | 25.14 ± 2.49 | .614 | .272 | .412 |
| SBP, mm Hg | 130.59 ± 17.22 | 130.53 ± 17.17 | 134.13 ± 19.98 | 128.44 ± 16.06 | .243 | .717 | .439 |
| DBP, mm Hg | 75.47 ± 11.77 | 75.49 ± 11.74 | 76.06 ± 12.72 | 70.22 ± 13.24 | .786 | .180 | .235 |
| LVEF, % | 59.57 ± 13.06 | 59.6 ± 13.06 | 54.03 ± 17.01 | 62.33 ± 10.97 | .397 | .718 | .498 |
| Previous stroke, % | 40 (2.80%) | 38 (2.74%) | 1 (3.13%) | 1 (11.11%) | .895 | .129 | .336 |
| Family history of CAD, n (%) | 280 (19.61%) | 289 (19.04%) | 7 (21.88%) | 2 (22.22%) | .686 | .840 | .982 |
| Diabetes Mellitus, n (%) | 502 (35.15%) | 513 (33.79%) | 13 (40.63%) | 5 (55.56%) | .419 | .195 | .425 |
| Hypertension, n (%) | 919 (64.36%) | 962 (63.37%) | 24 (75.00%) | 5 (55.56%) | .176 | .591 | .257 |
| Smoking, n (%) | 772 (54.06%) | 787 (51.84%) | 20 (62.50%) | 7 (77.78%) | .233 | .149 | .393 |
| Laboratory data | |||||||
| Hgb, mg/dL | 13.79 ± 1.82 | 13.81 ± 1.82 | 12.96 ± 1.95 | 13.26 ± 2.02 | .011 | .360 | .695 |
| Fasting sugar, mg/dL | 119.77 ± 41.94 | 119.39 ± 41.58 | 135.28 ± 56.61 | 121.67 ± 28.47 | .125 | .870 | .332 |
| Creatinine, mg/dL | 1.19 ± 1.01 | 1.18 ± 0.99 | 1.73 ± 1.66 | 1.12 ± 0.2 | .069 | .387 | .047 |
| eGFR, mL/min/1.73 m2 | 77.82 ± 28.57 | 78.24 ± 28.56 | 61.86 ± 27.62 | 69.07 ± 14.86 | .001 | .103 | .458 |
| Cholesterol, mg/dL | 163.16 ± 36.34 | 163.77 ± 36.81 | 162.16 ± 37.86 | 148.33 ± 17.78 | .806 | .036 | .133 |
| TG, mg/dL | 137.19 ± 85.26 | 137.36 ± 85.84 | 137.87 ± 100.55 | 105.44 ± 31.28 | .974 | .016 | .128 |
| HDL-C, mg/dL | 42.3 ± 10.82 | 42.53 ± 11.13 | 42.15 ± 10.51 | 41.1 ± 12.28 | .852 | .738 | .801 |
| LDL-C, mg/dL | 94.91 ± 29.91 | 95.43 ± 30.03 | 88.67 ± 25.61 | 86.01 ± 17.46 | .207 | .364 | .773 |
| Medications | |||||||
| Statin use, n (%) | 1070 (74.93%) | 1143 (75.30%) | 18 (56.25%) | 7 (77.78%) | .014 | .866 | .242 |
| RAS blockade, n (%) | 939 (65.76%) | 908 (65.47%) | 22 (68.75%) | 9 (100.00%) | .699 | .030 | .054 |
| ACEI, n (%) | 310 (21.71%) | 298 (21.49%) | 11 (34.38%) | 1 (11.11%) | .081 | .450 | .175 |
| ARB, n (%) | 634 (44.40%) | 615 (44.34%) | 11 (34.38%) | 8 (88.89%) | .262 | .007 | .004 |
| Antiplatelets, n (%) | 1329 (93.07%) | 1291 (93.08%) | 30 (93.75%) | 8 (88.89%) | .882 | .622 | .621 |
| Anticoagulants, n (%) | 41 (2.87%) | 38 (2.74%) | 2 (6.25%) | 1 (11.11%) | .236 | .129 | .621 |
| Beta-blocker, n (%) | 955 (66.88%) | 930 (67.05%) | 21 (65.63%) | 4 (44.44%) | .865 | .151 | .250 |
| Biomarkers | |||||||
| hsCRP, mg/dL | 0.34 ± 0.95 | 0.34 ± 0.96 | 0.3 ± 0.53 | 0.16 ± 0.15 | .750 | .013 | .260 |
| Adiponectin, ng/mL | 7572.09 ± 12801.19 | 7560.88 ± 13055.86 | 8174.13 ± 6779.52 | 6688.13 ± 3451.39 | .688 | .527 | .560 |
| LpPLa2, ng/mL | 153.04 ± 301.46 | 146.97 ± 287.41 | 302 ± 526.46 | 183.75 ± 408.6 | .174 | .721 | .569 |
| IL6, pg/mL | 2.95 ± 4.76 | 2.95 ± 4.85 | 3.21 ± 2.71 | 2.45 ± 1.51 | .661 | .402 | .456 |
| TNF-a, pg/mL | 3.71 ± 4.28 | 3.72 ± 4.36 | 3.43 ± 2.15 | 3.48 ± 2.81 | .558 | .878 | .960 |
| MMP-9, pg/mL | 573.11 ± 437.28 | 569.62 ± 439.29 | 648.73 ± 365.61 | 619.52 ± 502.48 | .394 | .750 | .861 |
| BNP, pg/mL | 78.32 ± 219.47 | 76.42 ± 219.75 | 159.01 ± 224.76 | 85.61 ± 53.93 | .036 | .638 | .100 |
| NT-proBNP, pg/mL | 339.95 ± 641.16 | 333.57 ± 636.16 | 620.1 ± 833.47 | 327.16 ± 447.52 | .062 | .976 | .320 |
| CXCL16, pg/mL | 387.05 ± 194.94 | 388.54 ± 195.82 | 351.81 ± 158.17 | 283.47 ± 143.57 | .293 | .108 | .251 |
| Myeloperoxidase, ng/mL | 758.45 ± 590.52 | 752.32 ± 584 | 1064.66 ± 761.48 | 615.25 ± 679.94 | .028 | .483 | .118 |
| FABP3, pg/mL | 3820.48 ± 6612.37 | 3764.08 ± 6534.85 | 6488.74 ± 9775.58 | 3023.89 ± 778.65 | .127 | .030 | .056 |
| FABP4, pg/mL | 8232.14 ± 20369.45 | 8158.4 ± 20431.3 | 12784.73 ± 20083.51 | 3409.36 ± 4030.18 | .205 | .008 | .018 |
| LIGHT, pg/mL | 291.7 ± 475.94 | 294.81 ± 480.33 | 216 ± 300.69 | 81.62 ± 87.69 | .159 | <.0001 | .033 |
| NGAL, ng/mL | 426.31 ± 692.25 | 422.29 ± 686.5 | 654.74 ± 955.64 | 234.44 ± 193.62 | .181 | .020 | .026 |